Development of the business case for a Schistosomiasis vaccine

MMGH supported the Bill & Melinda Gates Foundation in assessing the public health and financial viability of a vaccine against Schistosomiasis. MMGH coordinated a group of experts in developing vaccine use cases and Preferred Product Characteristics, worked with modellers from the Imperial College London and the University of Warwick to assess its epidemiological and economic impact, assessed the regulatory, product development and vaccine delivery strategy, and assembled its public health value proposition.